Fig. 3: Treatment patterns 12 months prior to (pre-index) and 12 months following (post-index) MITT initiation in the overall population. | npj Primary Care Respiratory Medicine

Fig. 3: Treatment patterns 12 months prior to (pre-index) and 12 months following (post-index) MITT initiation in the overall population.

From: Characteristics and treatment patterns of patients with asthma on multiple-inhaler triple therapy in Spain

Fig. 3

Percentages may not total 100% due to rounding. *ICS/LABA category includes: ICS/LABA, ICS/LABA/anti-leukotrienes, ICS/LABA/OCS, ICS/LABA/OCS/SAMA, ICS/LABA/anti-leukotrienes/OCS; †other category includes: ICS, ICS/LAMA, ICS/anti-leukotrienes, ICS/OCS, ICS/OCS/LAMA, LABA/LAMA, LABA/anti-leukotrienes, LAMA, LAMA/anti-leukotrienes, anti-leukotrienes, OCS, OCS/LAMA, OCS/LAMA/anti-leukotrienes. ICS inhaled corticosteroid, LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist, MITT multiple-inhaler triple therapy, OCS oral corticosteroid, SABA short-acting β2-agonist, SAMA short-acting muscarinic antagonist.

Back to article page